Cytokinetics
CYTK
$62.33
-0.84%
Cytokinetics Inc. is a late-stage, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for diseases in which muscle performance is compromised, including hypertrophic cardiomyopathy (HCM), amyotrophic lateral sclerosis, heart failure, and spinal muscular atrophy. With a market capitalization of roughly $7.6-9.1 billion and only 673 employees, Cytokinetics is a high-conviction, science-driven specialty player whose identity is now anchored on aficamten (approved as MYQORZO), a cardiac myosin inhibitor positioned to compete directly with Bristol Myers Squibb's Camzyos in the HCM market. The investor narrative has shifted decisively from pure clinical-stage binary risk to a commercial launch story: recent coverage highlights MYQORZO's potential to capture significant HCM share, while competitive commentary on Camzyos' long-term efficacy keeps the debate centered on label differentiation, launch trajectory, and payer access. At the same time, the stock's sharp underperformance versus the broader market reflects investor anxiety over the cash burn required to commercialize a first product, the dilutive equity raise executed in Q2 2026, and the gap between sell-side long-term revenue optimism and currently modest reported product revenue.…
CYTK
Cytokinetics
$62.33
Related headlines
Investment Opinion: Should I buy CYTK Today?
We rate CYTK a Hold, balancing the strong analyst consensus (20 analysts, mean rating 1.48, average target $109.40 implying 76.6% upside) against the significant execution risks and cash burn. The core thesis is that MYQORZO's launch is progressing, with sequential product revenue growth to $25.33 million in Q2 2026, but the company is burning ~$160 million per quarter and will likely need further financing, making the risk/reward balanced at current levels. Supporting evidence includes the 91.4% gross margin on product revenue, which demonstrates the product's profitability at scale, and the forward PS of ~3.3x on consensus 2027 revenue of $2.29 billion, which is in line with specialty pharma peers. However, the trailing PS of 86.6x and negative earnings (EPS -$1.50 in Q2 2026) highlight the valuation disconnect. The analyst consensus is overwhelmingly positive, with a mean rating of 1.48 and a target range of $85-$146, but the stock's 22.7% decline over 3 months and -25.4% relative underperformance versus SPY suggest the market is skeptical. Key risks include the intense competition from Camzyos, the need for additional capital, and the potential for slower-than-expected payer access. We would upgrade to Buy if MYQORZO's quarterly product revenue exceeds $40 million with a clear path to profitability, or if the stock price approaches the 52-week low of $54.30 while fundamentals remain intact. We would downgrade to Sell if product revenue growth stalls or if another large equity raise is announced at a discount. On valuation, CYTK is fairly valued on forward sales but expensive on trailing metrics; the stock is not cheap, but the forward estimates justify a Hold rating.
Sign up to view all
CYTK 12-Month Price Forecast
We have a neutral stance on CYTK with medium confidence. The company is at a critical juncture with MYQORZO's launch, and while the analyst community is overwhelmingly bullish (20 analysts, mean rating 1.48, average target $109.40), the market is skeptical given the stock's 22.7% decline over 3 months and significant cash burn. The forward valuation of ~3.3x 2027 sales is not unreasonable, but the path to profitability is uncertain and may require further dilution. We would upgrade to bullish if product revenue accelerates meaningfully (e.g., >$40 million quarterly) and cash burn narrows, or if the stock approaches the 52-week low of $54.30 with stable fundamentals. We would downgrade to bearish if product revenue growth stalls or if another large equity raise is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cytokinetics's 12-month outlook, with a consensus price target around $109.20 and implied upside of +75.2% versus the current price.
Average Target
$109.20
0 analysts
Implied Upside
+75.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$81 - $146
Analyst target range
Coverage is robust for a company of this size, with 20 analysts and a consensus recommendation of "strong_buy" (mean rating 1.48 on a 1-5 scale where 1 is Strong Buy). The average target price of $109.40 implies roughly +76.6% upside from the current $61.95, and even the lowest target of $85.00 sits about 37.2% above the market price — a striking disconnect that indicates the sell-side is valuing the stock on forward launch economics rather than trailing results. Consensus estimated EPS of $3.83 (range $2.68-5.68) and estimated revenue of $2.29 billion confirm that analysts are underwriting a rapid, large-scale commercial ramp; the bullish tilt is broad-based, with recent actions including UBS upgrading to Buy from Neutral on June 29, 2026, and reiterated Buy/Overweight/Outperform ratings from HC Wainwright, JP Morgan, Barclays, Truist, RBC, Citizens, Needham, and Mizuho through August 2026. The target range of $85.00 to $146.00 is wide — a spread of $61, or roughly 56% of the average target — which signals meaningful disagreement about launch trajectory and peak-share assumptions rather than about the asset's viability. The high target of $146.00 likely assumes rapid HCM share capture against Camzyos, multiple expansion on de-risked launch data, and pipeline optionality from the broader muscle-activator platform; the low target of $85.00 still embeds substantial upside but likely discounts slower payer access, competitive pressure from Camzyos' long-term efficacy data, and further dilution from financing needs. Notably, no analyst has moved to a Hold or Sell despite the 22.7% three-month decline and 25.4% relative underperformance versus SPY, creating a sharp divergence between price action and published conviction — a setup that either validates a contrarian opportunity or warns that estimates and ratings are stale relative to the deteriorating tape.
Bulls vs Bears: CYTK Investment Factors
The bull case rests on a successful launch of MYQORZO, with sequential product revenue growth, a strong analyst consensus (20 analysts, mean rating 1.48, average target $109.40), and a forward valuation that appears reasonable at ~3.3x estimated 2027 sales. However, the bear case is equally compelling: massive cash burn (-$580.71 million TTM FCF), deeply negative earnings, significant dilution, and a stock in a clear downtrend with -25.4% relative underperformance versus SPY over 3 months. The most important tension is whether MYQORZO can ramp fast enough to justify the current cash burn and valuation before the company needs another dilutive raise. The evidence currently favors the bear side on price action and financials, but the analyst consensus and forward revenue estimates suggest the sell-side sees a path to profitability that the market is discounting.
Bullish
- Analyst consensus strong buy with 76.6% upside: All 20 covering analysts rate CYTK a strong buy (mean 1.48), with an average target of $109.40 implying +76.6% upside from $61.95. Even the lowest target of $85.00 is 37.2% above the current price, indicating the sell-side values the stock on forward launch economics rather than trailing results.
- MYQORZO launch driving sequential product revenue growth: Q2 2026 net product revenue reached $25.33 million, up from $19.36 million in Q1 and $17.76 million in Q4 2025, confirming commercial traction. Product revenue now dominates the top line, with collaboration revenue only $3.29 million, signaling a successful transition to a commercial-stage company.
- Attractive forward valuation on consensus estimates: While trailing PS is 86.6x, the forward PS based on consensus 2027 revenue of $2.29 billion is only ~3.3x, in line with scaled specialty pharma peers. The forward PE of -13.88 on estimated EPS of $3.83 implies the Street expects a swing to profitability within the forecast horizon.
- Strong gross margins support scalable economics: Q2 2026 gross margin was 91.4% on product revenue, consistent with branded specialty pharma economics. This high margin demonstrates the product's potential for significant profitability once commercialization costs are absorbed.
Bearish
- Massive cash burn with no sign of narrowing: Trailing free cash flow is -$580.71 million, and Q2 2026 operating cash flow was -$159.84 million, with quarterly FCF of -$164.17 million. The company remains entirely dependent on external financing to bridge to self-funding.
- Deeply negative profitability and widening losses: Q2 2026 net income was -$198.76 million (EPS -$1.50), worse than -$134.37 million in Q2 2025, as R&D ($97.81M) and G&A ($104.40M) scaled with launch preparation. Interest expense of $34.83 million now materially burdens the P&L.
- Significant dilution from equity raise: Shares outstanding rose from 123.3 million to 132.1 million sequentially due to the $798.15 million equity raise in Q2 2026. This dilution reduces per-share value and may continue if further financing is needed.
- Stock in corrective downtrend, underperforming market: CYTK is down 22.7% over 3 months and 10.7% over 1 month, with relative strength versus SPY at -25.4% and -11.9% respectively. The stock sits at $61.95, only 14.1% above its 52-week low of $54.30, signaling broken momentum.
CYTK Technical Analysis
CYTK is in a corrective downtrend within a broader one-year range, with the stock at $61.95 versus a 52-week high of $88.31 and a 52-week low of $54.30, placing it at roughly 22.5% of its 52-week range — deep in the lower quartile and only about 14.1% above the annual low. The 1-year change of +5.07% masks a deteriorating intermediate trend, and the fact that price sits far closer to the floor than the ceiling signals that momentum has broken down rather than consolidated at highs. This positioning is characteristic of a post-catalyst fade: the stock is not yet a falling knife at multi-year lows, but it lacks the momentum signature of a stock near highs. Recent momentum is decisively negative and accelerating to the downside: the 1-month change of -10.72% and 3-month change of -22.74% show a sequential worsening of the decline, while the 6-month change of -7.14% and YTD change of just +0.36% confirm that all of 2026's gains have been erased. Relative strength is uniformly weak — -11.94% versus SPY over 1 month, -25.43% over 3 months, and -14.62% over 6 months — meaning the underperformance is not a sector-wide phenomenon but stock-specific de-rating. The 1-month trend conflicts sharply with the positive 1-year figure, a classic divergence that typically signals either a trend reversal or a deep mean-reversion setup; absent a volume-backed reversal, the weight of evidence favors continued distribution. Key levels are well defined: support clusters at the $54.30 52-week low, with the $59.58-61.12 zone (April and October lows) acting as the immediate battleground, while resistance sits at the $88.31 high with intermediate supply near $80-82 where the stock repeatedly failed in July and August. A breakdown below $54.30 would confirm a new leg lower and likely trigger momentum-driven selling, whereas a reclaim of $80+ would be required to repair the trend. Volatility risk is unusually asymmetric: beta of just 0.408 versus the market suggests low systematic co-movement, but the -29.96% max drawdown and 9.28 short ratio indicate that idiosyncratic, event-driven swings dominate — position sizing should reflect gap risk around clinical, regulatory, and launch datapoints rather than index beta.
Beta
0.41
0.41x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$54-$88
Price range past year
Annual Return
+13.8%
Cumulative gain past year
| Period | CYTK Return | S&P 500 |
|---|---|---|
| 1m | -7.8% | -1.2% |
| 3m | -22.8% | +3.4% |
| 6m | -4.6% | +7.0% |
| 1y | +13.8% | +14.4% |
| ytd | +1.0% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CYTK Fundamental Analysis
Revenue is small, lumpy, and currently decelerating on a reported basis: Q2 2026 revenue was $31.91 million, down 52.2% year-over-year from $66.77 million in Q2 2025, a comparison distorted by prior-period collaboration and milestone recognition. The sequential trend is more constructive — $19.36 million in Q1 2026 and $17.76 million in Q4 2025 — and segment disclosure shows $25.33 million of net product revenue versus $3.29 million of collaboration revenue, confirming that MYQORZO's commercial launch is now the primary growth engine. Still, the absolute revenue base is tiny relative to a $7.6 billion market cap, and the investment case rests almost entirely on the forward trajectory: consensus estimated revenue of $2.29 billion (range $1.76-3.14 billion) implies an order-of-magnitude step-up that has yet to appear in reported results. Profitability remains deeply negative: Q2 2026 net income was -$198.76 million with diluted EPS of -$1.50, operating income of -$175.88 million, and EBITDA of -$191.75 million, while gross margin was a strong 91.4% on product revenue. The loss widened from -$134.37 million in Q2 2025 as R&D of $97.81 million and G&A/SG&A of $104.40 million scaled with launch preparation, and interest expense of $34.83 million now materially burdens the P&L. The 91.4% gross margin is consistent with branded specialty pharma economics and shows the product can be highly profitable at scale, but operating margin of -551% (on the reported revenue base) underscores that commercialization costs currently dwarf the top line. Balance-sheet and cash-flow risk is the central fundamental issue: trailing free cash flow is -$580.71 million, Q2 2026 operating cash flow was -$159.84 million, and quarterly FCF of -$164.17 million shows no sign of narrowing. The company funded this via $798.15 million of common stock issued in Q2 2026, lifting cash to $258.38 million and producing a current ratio of 4.53x — ample near-term liquidity but achieved through significant dilution (shares outstanding rose from 123.3 million to 132.1 million sequentially). Debt-to-equity of -1.95 and negative book value (P/B of -11.56) reflect accumulated deficits and an equity base distorted by losses; ROE of 1.19 is not economically meaningful given negative equity. The company is entirely dependent on external financing and launch execution to bridge to self-funding, making the cash runway and any future capital raises the key fundamental variable.
Quarterly Revenue
$31914000.0B
2026-06
Revenue YoY Growth
-52.2%
YoY Comparison
Gross Margin
91.4%
Latest Quarter
Free Cash Flow
$-580714999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CYTK Overvalued?
Because Cytokinetics reported negative net income (-$198.76 million in Q2 2026) and negative EBITDA (-$191.75 million), the PE ratio is not meaningful — trailing PE of -9.72 and forward PE of -13.88 are artifacts of losses, and EV/EBITDA of -11.34 is similarly unusable. I therefore lead with the price-to-sales ratio, the appropriate metric for a pre-profit commercial-stage biotech: trailing PS is 86.6x and EV/Sales is 135.1x, extraordinarily high on current revenue but far more reasonable against consensus 2027 estimated revenue of $2.29 billion, which implies roughly 3.3x forward sales. The enormous gap between trailing and forward multiples is the entire valuation thesis — the market is pre-paying for a launch inflection that has not yet shown up in reported numbers, and the forward PE of -13.88 versus estimated EPS of $3.83 signals the Street expects a swing to meaningful profitability within the forecast horizon. Peer comparison is constrained by the absence of a formal industry-average dataset, but context is instructive: large-cap biotech and specialty pharma typically trade in the 3-6x forward sales range, so CYTK's ~3.3x forward PS is broadly in line with — not at a premium to — scaled commercial peers, while its 86.6x trailing PS is a function of a near-zero revenue denominator rather than an absolute valuation premium. The negative P/B of -11.56 and negative PCF of -14.95 are not comparable to sector norms and should be disregarded; the relevant spread is that CYTK trades at a discount to the profitability-adjusted multiples of established HCM competitors despite a differentiated asset, which the market is offsetting with launch-risk and financing-risk discounts. Historical context reinforces the de-rating: PS has collapsed from 3,406x in Q3 2025 and 436.7x in Q4 2025 to 352.6x in Q2 2026 as revenue scaled, and the stock's own PE band has ranged from roughly -5.4x to -15.1x over the past several years — all negative and therefore non-informative for mean reversion. What matters is that the current 86.6x trailing PS sits at the low end of the company's recent history precisely because revenue is finally materializing, suggesting the multiple compression is fundamentally driven rather than a valuation floor; the stock is neither cheap nor expensive on forward sales, but it embeds near-flawless execution of the MYQORZO launch.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Cytokinetics faces significant financial and operational risks. The company is burning cash at an alarming rate, with trailing free cash flow of -$580.71 million and Q2 2026 operating cash flow of -$159.84 million. Despite a $798.15 million equity raise in Q2 2026 that lifted cash to $258.38 million, the company remains dependent on external financing to fund operations. The loss widened to -$198.76 million in Q2 2026 from -$134.37 million a year earlier, as R&D ($97.81 million) and G&A ($104.40 million) scaled with launch preparation, and interest expense of $34.83 million now burdens the P&L. Revenue is lumpy and decelerating on a reported basis, with Q2 2026 revenue down 52.2% year-over-year to $31.91 million, though sequential product revenue growth is encouraging. The company's survival hinges on MYQORZO's commercial success and its ability to raise additional capital on favorable terms. Market and competitive risks are also pronounced. CYTK trades at a trailing PS of 86.6x, which is extremely high on current revenue but drops to ~3.3x on consensus 2027 revenue of $2.29 billion. The stock's beta of 0.408 suggests low correlation with the broader market, but its idiosyncratic volatility is high, with a max drawdown of -29.96% and a short ratio of 9.28 indicating significant bearish sentiment. Competition from Bristol Myers Squibb's Camzyos is intense, and recent news highlights Camzyos' long-term efficacy and strong sales growth, which could limit MYQORZO's market share. Additionally, the stock has underperformed the market significantly, with relative strength versus SPY at -25.4% over 3 months, reflecting investor anxiety over cash burn and dilution. The worst-case scenario would involve a slower-than-expected launch, payer access challenges, and another dilutive financing. In this scenario, the stock could retest its 52-week low of $54.30, representing a 12.4% decline from the current price of $61.95. A more severe outcome, such as a failed launch or competitive disruption, could push the stock below the 52-week low, with potential downside to the analyst low target of $85.00 (which is actually above the current price, so that's not a downside). Wait, the analyst low target is $85, which is above current price. So the downside is to the 52-week low of $54.30, or -12.4%. However, if the launch fails, the stock could fall further, perhaps to $40 or lower, but we don't have a specific target. We can reference the max drawdown of -29.96%, which from the current price would imply a drop to ~$43.40. So the realistic downside is -12.4% to the 52-week low, and potentially -30% in a severe scenario.
FAQ
The key risks include: 1) Financial risk: massive cash burn (-$580.71 million TTM FCF) requiring further financing, which could dilute shareholders. 2) Competitive risk: intense competition from Bristol Myers Squibb's Camzyos, which has long-term efficacy data and strong sales growth. 3) Execution risk: slower-than-expected payer access and launch traction could disappoint. 4) Market risk: the stock has high idiosyncratic volatility (max drawdown -29.96%) and is in a downtrend, with relative strength versus SPY at -25.4% over 3 months. These risks are ranked from most to least severe, with financial risk being the most immediate.
Our 12-month forecast has three scenarios: Bull (30% probability) with a target range of $109.40-$146.00, assuming strong launch execution and analyst upgrades; Base (50% probability) with a target range of $85.00-$109.40, assuming steady growth and no major surprises; Bear (20% probability) with a target range of $54.30-$85.00, assuming slower launch and potential financing. The base case is most likely, with the key assumption that product revenue grows 20-30% sequentially and no additional equity raise occurs. The stock is currently trading at $61.95, below the base case range, suggesting potential upside if the base case materializes.
CYTK's valuation is complex due to negative earnings. On trailing metrics, it appears overvalued with a PS of 86.6x and EV/Sales of 135.1x, but these are distorted by a small revenue base. On forward estimates, the stock trades at ~3.3x consensus 2027 revenue of $2.29 billion, which is in line with specialty pharma peers. The market is pricing in a successful launch and profitability, as indicated by the forward PE of -13.88 on estimated EPS of $3.83. Therefore, the stock is fairly valued on forward sales but expensive on current fundamentals, implying the market expects significant growth.
CYTK is a high-risk, high-reward biotech stock that may be suitable for aggressive investors. The analyst consensus is strong buy with an average target of $109.40, implying 76.6% upside, but the stock has fallen 22.7% over 3 months due to cash burn concerns and competition. The biggest downside risk is a failed launch or another dilutive financing, which could push the stock to its 52-week low of $54.30 (-12.4%). For investors with a high risk tolerance and a long-term view, CYTK could be a good buy on weakness, but it is not suitable for conservative portfolios.
CYTK is more suitable for long-term investment (minimum 2-3 years) given the binary nature of the launch and the need for multiple quarters of execution to prove the commercial opportunity. The stock's beta of 0.408 suggests low market correlation, but its idiosyncratic volatility is high, with a max drawdown of -29.96% and a short ratio of 9.28, making it unsuitable for short-term trading unless one has specific event-driven insights. The company pays no dividend, so returns depend entirely on capital appreciation. Investors should be prepared for volatility and have a high risk tolerance. A suggested minimum holding period is 2-3 years to allow the launch to mature and the company to potentially reach profitability.